Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha; Alexander T H Wu; Wei Hwa Lee; Liang Shun Wang; Wan Wan Lin; Chiou Chung Yuan; Chi-Tai Yeh

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T H Wu, Wei Hwa Lee, Liang Shun Wang, Wan Wan Lin, Chiou Chung Yuan, Chi-Tai Yeh

研究成果: 雜誌貢獻 › 文章 › 同行評審

摘要

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

原文	英語
頁（從 - 到）	13255-13268
頁數	14
期刊	Oncotarget
卷	6
發行號	15
出版狀態	已發佈 - 2015

ASJC Scopus subject areas

腫瘤科

UN SDG

此研究成果有助於以下永續發展目標

其它文件與鏈接

Link to publication in Scopus

引用此

@article{bcb1182d0a184149b2195fcb2ac21554,

title = "Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer",

abstract = "According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.",

keywords = "Bruton's tyrosine kinase (Btk), Cancer stem cell (CSC), Cisplatin, Ibrutinib, Ovarian cancer, Spheroids",

author = "Zucha, {Muhammad Ary} and Wu, {Alexander T H} and Lee, {Wei Hwa} and Wang, {Liang Shun} and Lin, {Wan Wan} and Yuan, {Chiou Chung} and Chi-Tai Yeh",

year = "2015",

language = "English",

volume = "6",

pages = "13255--13268",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "15",

}

TY - JOUR

T1 - Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

AU - Zucha, Muhammad Ary

AU - Wu, Alexander T H

AU - Lee, Wei Hwa

AU - Wang, Liang Shun

AU - Lin, Wan Wan

AU - Yuan, Chiou Chung

AU - Yeh, Chi-Tai

PY - 2015

Y1 - 2015

N2 - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

AB - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

KW - Bruton's tyrosine kinase (Btk)

KW - Cancer stem cell (CSC)

KW - Cisplatin

KW - Ibrutinib

KW - Ovarian cancer

KW - Spheroids

UR - http://www.scopus.com/inward/record.url?scp=84931092005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931092005&partnerID=8YFLogxK

M3 - Article

C2 - 26036311

AN - SCOPUS:84931092005

SN - 1949-2553

VL - 6

SP - 13255

EP - 13268

JO - Oncotarget

JF - Oncotarget

IS - 15

ER -

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

摘要

ASJC Scopus subject areas

UN SDG

其它文件與鏈接

指紋

引用此